

David W Dodick

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6934703/david-w-dodick-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

261 papers	14,966 citations	65 h-index	118 g-index
276 ext. papers	18,356 ext. citations	8 avg, IF	7.06 L-index

#	Paper	IF	Citations
261	Migraine.. <i>Nature Reviews Disease Primers</i> , 2022 , 8, 2	51.1	16
260	Post-traumatic Headache: Pharmacologic Management and Targeting CGRP Signaling.. <i>Current Neurology and Neuroscience Reports</i> , 2022 , 1	6.6	1
259	Patient-Centered Treatment of Chronic Migraine With Medication Overuse: A Prospective, Randomized, Pragmatic Clinical Trial.. <i>Neurology</i> , 2022 ,	6.5	6
258	Stroke Telemedicine for Arizona Rural Residents, the Legacy Telestroke Study. <i>Telemedicine Reports</i> , 2022 , 3, 67-78	2	0
257	Sleep restriction alters cortical inhibition in migraine: A transcranial magnetic stimulation study.. <i>Clinical Neurophysiology</i> , 2022 , 139, 28-42	4.3	1
256	Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.. <i>Headache</i> , 2022 ,	4.2	2
255	Treatment of chronic migraine with medication overuse: A perspective.. <i>Headache</i> , 2022 , 62, 642-644	4.2	
254	Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 edition.. <i>Cephalalgia</i> , 2022 , 3331024221099035	6.1	
253	The impact of pre-morbid headaches on headache features and long-term health outcomes following traumatic brain injury: Insights from the American Registry for Migraine Research.. <i>Headache</i> , 2022 , 62, 566-576	4.2	0
252	Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache.. <i>Cephalalgia</i> , 2022 , 3331024221099841	6.1	0
251	207 OnabotA for CM: benefits beyond headache-day reduction. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A73.1-A73	5.5	
250	Migrainous infarction of the eye: Two cases of monocular ischemic complications associated with retinal migraine. <i>Cephalalgia</i> , 2021 , 3331024211056286	6.1	0
249	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. <i>Neurology</i> , 2021 , 96, 848-863	6.5	30
248	Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. <i>Headache</i> , 2021 , 61, 422-429	4.2	8
247	Impact of abuse on migraine-related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research. <i>Headache</i> , 2021 , 61, 740-754	4.2	4
246	Subconcussive brain vital signs changes predict head-impact exposure in ice hockey players. <i>Brain Communications</i> , 2021 , 3, fcb019	4.5	4
245	Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. <i>Journal of Headache and Pain</i> , 2021 , 22, 29	8.8	11

244	Migraine: integrated approaches to clinical management and emerging treatments. <i>Lancet, The</i> , 2021 , 397, 1505-1518	4.0	34
243	Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. <i>Cephalalgia</i> , 2021 , 41, 1135-1151	6.1	6
242	Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey study. <i>Headache</i> , 2021 , 61, 734-739	4.2	6
241	Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome. <i>Headache</i> , 2021 , 61, 766-776	4.2	8
240	Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial. <i>Cephalalgia</i> , 2021 , 41, 1053-1064	6.1	0
239	Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. <i>Headache</i> , 2021 , 61, 992-1003	4.2	8
238	Diagnosing Secondary and Primary Headache Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2021 , 27, 572-585	3	0
237	Mild traumatic brain injury affects the features of migraine. <i>Journal of Headache and Pain</i> , 2021 , 22, 80	8.8	2
236	Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. <i>Cephalalgia</i> , 2021 , 41, 340-352	6.1	19
235	A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. <i>Cephalalgia</i> , 2021 , 41, 305-317	6.1	8
234	Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2021 , 61, 103-116	4.2	3
233	Disability and Economic Loss Caused by Headache among Information Technology Workers in Korea. <i>Journal of Clinical Neurology (Korea)</i> , 2021 , 17, 546-557	1.7	2
232	Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. <i>European Journal of Neurology</i> , 2021 , 28, 1716-1725	6.4	40
231	CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache. <i>Cephalalgia</i> , 2021 , 41, 749-759	6.1	3
230	Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of Tolerability and Effectiveness in Migraine Patients using Preventive Treatment (ATTAIN) study. <i>Headache</i> , 2021 , 61, 438-454	4.2	8
229	Systematic review of outcomes and endpoints in preventive migraine clinical trials. <i>Headache</i> , 2021 , 61, 253-262	4.2	11
228	Real-world efficacy, tolerability, and safety of ubrogepant. <i>Headache</i> , 2021 , 61, 620-627	4.2	9
227	Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial. <i>Journal of Pain Research</i> , 2021 , 14, 549-560	2.9	1

226	Systematic review of outcomes and endpoints in acute migraine clinical trials. <i>Headache</i> , 2021 , 61, 263-275	4.5	11
225	Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies. <i>Cephalalgia</i> , 2021 , 41, 1458-1466	6.1	0
224	Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 136	9	1
223	Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data. <i>Headache</i> , 2021 , 61, 1411-1420	4.2	6
222	Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial. <i>Headache</i> , 2021 , 61, 351-362	4.2	12
221	Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.. <i>JAMA Neurology</i> , 2021 ,	17.2	3
220	Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.. <i>Headache</i> , 2021 ,	4.2	3
219	Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. <i>Cephalalgia</i> , 2020 , 40, 1535-1550	6.1	6
218	Migraine and risk of stroke. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 593-604	5.5	41
217	Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. <i>Journal of Headache and Pain</i> , 2020 , 21, 23	8.8	65
216	Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. <i>Cephalalgia</i> , 2020 , 40, 892-902	6.1	22
215	The need for continued care after sponsor closure - Authors' reply. <i>Lancet Neurology</i> , 2020 , 19, 205-206	20.6	1
214	Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. <i>Cephalalgia</i> , 2020 , 40, 935-948	6.1	47
213	Sensory Hypersensitivity Symptoms in Migraine With vs Without Aura: Results From the American Registry for Migraine Research. <i>Headache</i> , 2020 , 60, 506-514	4.2	7
212	Vascular safety of erenumab for migraine prevention. <i>Neurology</i> , 2020 , 94, e497-e510	6.5	39
211	Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies. <i>Headache</i> , 2020 , 60, 348-359	4.2	24
210	Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Headache</i> , 2020 , 60, 58-70	4.2	5
209	Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. <i>Headache</i> , 2020 , 60, 416-429	4.2	23

208	The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort. <i>Headache</i> , 2020 , 60, 337-347	4.2	15
207	Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis. <i>Pain and Therapy</i> , 2020 , 9, 683-694	3.6	1
206	Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. <i>Headache</i> , 2020 , 60, 2220-2231	4.2	18
205	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. <i>Cephalalgia</i> , 2020 , 40, 1026-1044	6.1	47
204	Impact of Depression and Anxiety Symptoms on Patient-Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR). <i>Headache</i> , 2020 , 60, 1910-1919	4.2	8
203	The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine. <i>Pain and Therapy</i> , 2020 , 9, 695-707	3.6	2
202	The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving 50%, 75%, and 100% Response. <i>Headache</i> , 2020 , 60, 2026-2040	4.2	4
201	Effect of Migraine on Pregnancy Planning: Insights From the American Registry for Migraine Research. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 2079-2089	6.4	9
200	Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. <i>Lancet Neurology</i> , 2020 , 19, 727-737	74.1	64
199	Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. <i>Neurology</i> , 2020 , 95, e2487-e2499	6.5	44
198	Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data. <i>Journal of Primary Care and Community Health</i> , 2020 , 11, 2150132720963680	2.1	10
197	Proposed new diagnostic criteria for chronic migraine. <i>Cephalalgia</i> , 2020 , 40, 399-406	6.1	26
196	Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache. <i>Cephalalgia</i> , 2020 , 40, 68-78	6.1	8
195	Post-traumatic headache: epidemiology and pathophysiological insights. <i>Nature Reviews Neurology</i> , 2019 , 15, 607-617	15	68
194	CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. <i>Cephalalgia</i> , 2019 , 39, 1762-1775	6.1	39
193	Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches. <i>Headache</i> , 2019 , 59, 509-517	4.2	5
192	CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. <i>Cephalalgia</i> , 2019 , 39, 445-458	6.1	82
191	Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. <i>Cephalalgia</i> , 2019 , 39, 1075-1085	6.1	64

190	Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. <i>Cephalalgia</i> , 2019 , 39, 1455-1464	6.1	55
189	Pathophysiology, prevention, and treatment of medication overuse headache. <i>Lancet Neurology, The</i> , 2019 , 18, 891-902	24.1	82
188	Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data. <i>Cephalalgia</i> , 2019 , 39, 945-956	6.1	19
187	Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. <i>Headache</i> , 2019 , 59, 1240-1252	4.2	50
186	Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 939-944	5.5	16
185	Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists. <i>Current Treatment Options in Neurology</i> , 2019 , 21, 17	4.4	9
184	Tau Positron-Emission Tomography in Former National Football League Players. <i>New England Journal of Medicine</i> , 2019 , 380, 1716-1725	59.2	95
183	Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study. <i>Cephalalgia</i> , 2019 , 39, 873-882	6.1	19
182	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. <i>Cephalalgia</i> , 2019 , 39, 687-710	6.1	83
181	Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2019 , 59, 1310-1323	4.2	33
180	Trial of Galcanezumab in Prevention of Episodic Cluster Headache. <i>New England Journal of Medicine</i> , 2019 , 381, 132-141	59.2	111
179	World Brain Day 2019: migraine, the painful truth. <i>Lancet Neurology, The</i> , 2019 , 18, 914	24.1	12
178	Anatomical landmarks for localizing the otic ganglion: A possible new treatment target for headache disorders. <i>Cephalalgia Reports</i> , 2019 , 2, 251581631985076	0.7	0
177	Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial. <i>Lancet Neurology, The</i> , 2019 , 18, 1081-1090	24.1	32
176	Ubrogepant for the Treatment of Migraine. <i>New England Journal of Medicine</i> , 2019 , 381, 2230-2241	59.2	138
175	Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials. <i>Cephalalgia</i> , 2019 , 39, 52-60	6.1	17
174	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2018 , 38, 815-832	6.1	141
173	Migraine. <i>Lancet, The</i> , 2018 , 391, 1315-1330	40	191

172	A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). <i>Cephalalgia</i> , 2018 , 38, 1038-1048	6.1	80
171	ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. <i>Cephalalgia</i> , 2018 , 38, 1026-1037	6.1	272
170	A Phase-by-Phase Review of Migraine Pathophysiology. <i>Headache</i> , 2018 , 58 Suppl 1, 4-16	4.2	140
169	Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2018 , 75, 187-193	17.2	107
168	Sub-classifying patients with mild traumatic brain injury: A clustering approach based on baseline clinical characteristics and 90-day and 180-day outcomes. <i>PLoS ONE</i> , 2018 , 13, e0198741	3.7	14
167	Fremanezumab for preventive treatment of migraine: Functional status on headache-free days. <i>Neurology</i> , 2018 , 91, e1152-e1165	6.5	26
166	Vancouver Declaration on Global Headache Patient Advocacy 2018. <i>Cephalalgia</i> , 2018 , 38, 1899-1909	6.1	14
165	Treatment of Cluster Headache. <i>Annals of Indian Academy of Neurology</i> , 2018 , 21, S9-S15	0.9	9
164	Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences. <i>Headache</i> , 2018 , 58, 1408-1426	4.2	53
163	A Cross-Study Analysis for Reproducible Sub-classification of Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2018 , 9, 606	4.1	6
162	The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients. <i>Headache</i> , 2018 , 58, 973-985	4.2	5
161	Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. <i>JAMA Neurology</i> , 2018 , 75, 1080-1088	17.2	266
160	Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 1999-2008	27.4	245
159	Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. <i>Cephalalgia</i> , 2017 , 37, 560-570	6.1	41
158	Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes. <i>Headache</i> , 2017 , 57, 766-777	4.2	30
157	The Clinical Characteristics of Migraine 2017 , 189-200		
156	Central Circuits Promoting Chronification of Migraine 2017 , 139-155		
155	Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. <i>Cephalalgia</i> , 2017 , 37, 780-794	6.1	51

154	Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. <i>Neurology</i> , 2017 , 89, 1237-1243	6.5	98
153	A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, e1.63-e1	5.5	9
152	King-Devick Test identifies real-time concussion and asymptomatic concussion in youth athletes. <i>Neurology: Clinical Practice</i> , 2017 , 7, 464-473	1.7	14
151	Board Walk - September 2017. <i>Cephalalgia</i> , 2017 , 37, 1009-1010	6.1	
150	Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines. <i>Headache</i> , 2017 , 57, 1375-1384	4.2	32
149	The Non-Inferiority Margins in Migraine Research (NIMM) Survey. <i>Headache</i> , 2017 , 57, 729-736	4.2	2
148	Fremanezumab for the Preventive Treatment of Chronic Migraine. <i>New England Journal of Medicine</i> , 2017 , 377, 2113-2122	59.2	380
147	Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. <i>Cephalalgia</i> , 2017 , 37, 470-485	6.1	157
146	Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine. <i>Cephalalgia</i> , 2017 , 37, 1350-1372	6.1	20
145	The Effect of In-School Saccadic Training on Reading Fluency and Comprehension in First and Second Grade Students. <i>Journal of Child Neurology</i> , 2017 , 32, 104-111	2.5	13
144	Treatment of medication-overuse headache: A systematic review. <i>Cephalalgia</i> , 2016 , 36, 371-86	6.1	107
143	United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data. <i>Journal of Pain</i> , 2016 , 17, 1068-1080	5.2	91
142	Efficacy of (-)-Lacosamide in preclinical models of cephalic pain. <i>Pain Reports</i> , 2016 , 1,	3.5	17
141	TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. <i>Neurology</i> , 2016 , 87, 41-8	6.5	69
140	Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). <i>Cephalalgia</i> , 2016 , 36, 203-15	6.1	33
139	Headache research in 2015: progress in migraine treatment. <i>Lancet Neurology, The</i> , 2016 , 15, 4-5	24.1	14
138	Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , 2016 , 15, 382-90	24.1	246
137	Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database. <i>Cephalalgia</i> , 2016 , 36, 862-74	6.1	24

136	A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. <i>Cephalalgia</i> , 2016 , 36, 887-98	6.1	173
135	Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEQ Study. <i>Mayo Clinic Proceedings</i> , 2016 ,	6.4	83
134	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEQ) Study. <i>Headache</i> , 2016 , 56, 821-834	4.2	111
133	Procedural Headache Medicine in Neurology Residency Training: A Survey of US Program Directors. <i>Headache</i> , 2016 , 56, 79-85	4.2	13
132	Ice hockey summit II: zero tolerance for head hits and fighting. <i>PM and R</i> , 2015 , 7, 283-95	2.2	4
131	Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study. <i>Cephalalgia</i> , 2015 , 35, 959-68	6.1	90
130	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. <i>Lancet Neurology</i> , 2015 , 14, 1081-90	24.1	202
129	Milestone-compatible neurology resident assessments: A role for observable practice activities. <i>Neurology</i> , 2015 , 84, 2279-83	6.5	9
128	Response to Letter to the Editor. <i>Cephalalgia</i> , 2015 , 35, 1034-5	6.1	
127	Taking the headache out of migraine. <i>Neurology: Clinical Practice</i> , 2015 , 5, 317-325	1.7	6
126	Late-life migraine accompaniments: A narrative review. <i>Cephalalgia</i> , 2015 , 35, 894-911	6.1	44
125	Functional MRI of migraine. <i>Lancet Neurology</i> , 2015 , 14, 81-91	24.1	149
124	Site of effect of LY2951742 for migraine prophylaxis--authors' reply. <i>Lancet Neurology</i> , 2015 , 14, 32-3	24.1	3
123	Adherence to oral migraine-preventive medications among patients with chronic migraine. <i>Cephalalgia</i> , 2015 , 35, 478-88	6.1	214
122	Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. <i>Cephalalgia</i> , 2015 , 35, 271-84	6.1	77
121	Comprehensive management of patients presenting to the otolaryngologist for sinus pressure, pain, or headache. <i>Laryngoscope</i> , 2015 , 125, 303-10	3.6	28
120	Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study. <i>Cephalalgia</i> , 2015 , 35, 344-58	6.1	118
119	Occipital Nerve Stimulation for Migraine: Update from Recent Multicenter Trials. <i>Progress in Neurological Surgery</i> , 2015 , 29, 117-26	1.4	7

118	Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 408-14	6.4	31
117	Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 996-1001	5.5	83
116	Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. <i>Journal of Pain</i> , 2015 , 16, 164-75	5.2	38
115	Migraine and the vascular system: much has been learned but still a long way to go. <i>Cephalalgia</i> , 2015 , 35, 83-4	6.1	2
114	Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. <i>Cephalalgia</i> , 2014 , 34, 594-604	6.1	46
113	Targeting TRP channels for novel migraine therapeutics. <i>ACS Chemical Neuroscience</i> , 2014 , 5, 1085-96	5.7	59
112	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <i>Lancet Neurology</i> , 2014 , 13, 1100-1107	24.1	275
111	Enhanced pain-induced activity of pain-processing regions in a case-control study of episodic migraine. <i>Cephalalgia</i> , 2014 , 34, 947-58	6.1	99
110	Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Neurology</i> , 2014 , 13, 885-92	24.1	269
109	Operational diagnostic criteria for chronic migraine: expert opinion. <i>Headache</i> , 2014 , 54, 1258-66	4.2	26
108	Refractory headaches treated with bilateral occipital and temporal region stimulation. <i>Medical Devices: Evidence and Research</i> , 2014 , 7, 55-9	1.5	4
107	BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. <i>Cephalalgia</i> , 2014 , 34, 114-25	6.1	181
106	In response to: time to re-think the Zurich Guidelines? A critique on the consensus statement on concussion in Sport; the 4th International Conference on Concussion in Sport, held in Zurich, November 2012. <i>Clinical Journal of Sport Medicine</i> , 2014 , 24, 521	3.2	
105	Atypical age-related cortical thinning in episodic migraine. <i>Cephalalgia</i> , 2014 , 34, 1115-24	6.1	38
104	OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. <i>Journal of the Neurological Sciences</i> , 2013 , 331, 48-56	3.2	122
103	Expert consensus recommendations for the performance of peripheral nerve blocks for headaches--a narrative review. <i>Headache</i> , 2013 , 53, 437-46	4.2	142
102	Chronic migraine--classification, characteristics and treatment. <i>Nature Reviews Neurology</i> , 2012 , 8, 162-71	5	104
101	Migraine headache is present in the aura phase: a prospective study. <i>Neurology</i> , 2012 , 79, 2044-9	6.5	65

100	Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. <i>Cephalalgia</i> , 2012 , 32, 1165-79	6.1	224
99	Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. <i>Cephalalgia</i> , 2011 , 31, 851-60	6.1	44
98	Migraine and Other Comorbidities: Obesity, Temporomandibular Disorders and Contact Points 2011 , 112-121		
97	Optimal Management of Migraine Taking into Account Comorbidities and Positive Side Effects 2011 , 132-137		2
96	Migraine and Other Pain Disorders 2011 , 81-95		
95	Comorbidity of Migraine and Epilepsy 2011 , 59-80		
94	Migraine and Medication Overuse 2011 , 96-111		1
93	Migraine and Stroke 2011 , 14-26		1
92	Psychiatric Comorbidity in Migraine 2011 , 1-13		0
91	Patent Foramen Ovale and Migraine 2011 , 41-58		
90	Cardiovascular Disorders 2011 , 27-40		
89	Diagnostic criteria for headache due to spontaneous intracranial hypotension: a perspective. <i>Headache</i> , 2011 , 51, 1442-4	4.2	96
88	Suboccipital steroid injections for cluster headache. <i>Lancet Neurology</i> , 2011 , 10, 867-9	24.1	4
87	Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. <i>Cephalalgia</i> , 2011 , 31, 712-22	6.1	205
86	Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. <i>Cephalalgia</i> , 2011 , 31, 271-85	6.1	294
85	Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. <i>Neurologist</i> , 2011 , 17, 297-9	1.6	17
84	Chronic daily headache: an evidence-based and systematic approach to a challenging problem. <i>Neurology</i> , 2011 , 76, S37-43	6.5	24
83	Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. <i>Cephalalgia</i> , 2011 , 31, 296-300	6.1	11

82	The Medical History: The Key to Correct Headache Diagnosis 2011 , 181-196		1
81	Pearls: headache. <i>Seminars in Neurology</i> , 2010 , 30, 74-81	3.2	62
80	Headache attributed to disorders of homeostasis. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2010 , 97, 627-42	3	2
79	Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. <i>Brain</i> , 2010 , 133, 2475-88	11.2	79
78	55-Year-old man with thunderclap headache. <i>Mayo Clinic Proceedings</i> , 2010 , 85, e44-7	6.4	2
77	Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. <i>Headache</i> , 2010 , 50, 1406-18	4.2	148
76	Triptan-induced latent sensitization: a possible basis for medication overuse headache. <i>Annals of Neurology</i> , 2010 , 67, 325-37	9.4	126
75	Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. <i>Lancet Neurology</i> , 2010 , 9, 373-80	24.1	299
74	OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. <i>Headache</i> , 2010 , 50, 921-36	4.2	601
73	Crescendo transient Aura attacks: a transient ischemic attack mimic caused by focal subarachnoid hemorrhage. <i>Stroke</i> , 2009 , 40, 3725-9	6.7	47
72	Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. <i>Clinical Therapeutics</i> , 2009 , 31, 542-59	3.5	95
71	Headache: challenging conventional wisdom. <i>Lancet Neurology</i> , 2009 , 8, 12-4	24.1	1
70	Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. <i>Headache</i> , 2009 , 49, 1153-62	4.2	90
69	The face of chronic migraine: epidemiology, demographics, and treatment strategies. <i>Neurologic Clinics</i> , 2009 , 27, 467-79	4.5	15
68	Examining the essence of migraine--is it the blood vessel or the brain? A debate. <i>Headache</i> , 2008 , 48, 661-7	4.2	37
67	Reflections and speculations on refractory migraine: why do some patients fail to improve with currently available therapies?. <i>Headache</i> , 2008 , 48, 828-37	4.2	5
66	CASE 1: the well-intentioned triptan prescriber. <i>Headache</i> , 2008 , 48, 862-4	4.2	
65	Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. <i>Headache</i> , 2008 , 48, 1087-95	4.2	30

64	Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. <i>Lancet, The</i> , 2008 , 372, 2115-23	4.0	423
63	Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database. <i>Headache</i> , 2008 , 48, 184-93	4.2	19
62	Headache and Other Craniofacial Pain 2008 , 2011-2062		4
61	Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. <i>Headache</i> , 2007 , 47, 170-80	4.2	350
60	The Sinus, Allergy and Migraine Study (SAMS). <i>Headache</i> , 2007 , 47, 213-24	4.2	153
59	Familial hemiplegic migraine: permanent attack-related neurologic deficits. <i>Headache</i> , 2007 , 47, 1210-2	4.2	9
58	The impact of topiramate on health-related quality of life indicators in chronic migraine. <i>Headache</i> , 2007 , 47, 1398-408	4.2	46
57	Thunderclap headache: an approach to a neurologic emergency. <i>Current Neurology and Neuroscience Reports</i> , 2007 , 7, 101-9	6.6	20
56	Spontaneous intracranial hypotension. <i>Current Pain and Headache Reports</i> , 2007 , 11, 56-61	4.2	35
55	Narrative review: reversible cerebral vasoconstriction syndromes. <i>Annals of Internal Medicine</i> , 2007 , 146, 34-44	8	630
54	Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. <i>CNS Drugs</i> , 2007 , 21, 73-82	6.7	31
53	Thunderclap headache. <i>Lancet Neurology, The</i> , 2006 , 5, 621-31	24.1	209
52	Pathophysiology and management of transformed migraine and medication overuse headache. <i>Seminars in Neurology</i> , 2006 , 26, 232-41	3.2	24
51	Clinical practice. Chronic daily headache. <i>New England Journal of Medicine</i> , 2006 , 354, 158-65	59.2	147
50	Thunderclap stroke: embolic cerebellar infarcts presenting as thunderclap headache. <i>Headache</i> , 2006 , 46, 520-2	4.2	33
49	Botulinum Toxin Type A (Botox) for Prophylactic Treatment of Chronic Daily Headache: A Response. <i>Headache</i> , 2006 , 46, 529-530	4.2	2
48	Central sensitization theory of migraine: clinical implications. <i>Headache</i> , 2006 , 46 Suppl 4, S182-91	4.2	178
47	DHE in the pharmacotherapy of migraine: potential for a larger role. <i>Headache</i> , 2006 , 46 Suppl 4, S212-20.	4.2	34

46	Chronic Daily Headache 2006 , 70-77		1
45	Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. <i>CNS Drugs</i> , 2005 , 19, 125-36	6.7	43
44	Triptan nonresponder studies: implications for clinical practice. <i>Headache</i> , 2005 , 45, 156-62	4.2	99
43	Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. <i>Headache</i> , 2005 , 45, 315-24	4.2	180
42	Spontaneous CSF leak treated with percutaneous CT-guided fibrin glue. <i>Neurology</i> , 2005 , 64, 1818-9	6.5	56
41	Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. <i>Headache</i> , 2004 , 44, 414-25	4.2	274
40	Painful ophthalmoplegia: overview with a focus on Tolosa-Hunt syndrome. <i>Current Pain and Headache Reports</i> , 2004 , 8, 321-9	4.2	21
39	Indomethacin-responsive headache syndromes. <i>Current Pain and Headache Reports</i> , 2004 , 8, 19-26	4.2	70
38	Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project. <i>Current Pain and Headache Reports</i> , 2004 , 8, 435-42	4.2	13
37	Evaluation and management of asymptomatic carotid artery stenosis. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 937-44	6.4	23
36	Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. <i>Clinics in Dermatology</i> , 2004 , 22, 76-81	3	19
35	Revised 2004 International Classification of Headache Disorders: new headache types. <i>Canadian Journal of Neurological Sciences</i> , 2004 , 31, 304-14	1	15
34	Advances in migraine management: implications for managed care organizations. <i>Managed Care</i> , 2004 , 13, 45-51	0.3	12
33	Epidemiology and acute care of migraine headache. <i>Managed Care Interface</i> , 2004 , 17 Suppl D, 6-10; discussion 11-3		
32	Preventing migraine pharmacologically. <i>Managed Care Interface</i> , 2004 , 17 Suppl D, 14-7, 22; discussion 23-30		
31	Current and emerging treatment options for migraine and other primary headache disorders. <i>Expert Review of Neurotherapeutics</i> , 2003 , 3, 845-72	4.3	2
30	Clinical, anatomical, and physiologic relationship between sleep and headache. <i>Headache</i> , 2003 , 43, 282-92	4.2	184
29	Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. <i>Headache</i> , 2003 , 43 Suppl 1, S25-33	4.2	59

28	A review of the clinical efficacy and tolerability of almotriptan in acute migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2003 , 4, 1157-63	4	12
27	Patient-focused migraine management: establishing needs. <i>Drugs of Today</i> , 2003 , 39 Suppl D, 3-9	2.5	2
26	Sumatriptan versus eletriptan: which is best?. <i>Lancet Neurology, The</i> , 2002 , 1, 474	24.1	1
25	Thunderclap headache. <i>Current Pain and Headache Reports</i> , 2002 , 6, 226-32	4.2	6
24	Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. <i>Headache</i> , 2002 , 42, 21-7	4.2	17
23	Thunderclap headache. <i>Headache</i> , 2002 , 42, 309-15	4.2	39
22	Hemicrania continua: an indomethacin-responsive case with an underlying malignant etiology. <i>Headache</i> , 2002 , 42, 527-9	4.2	34
21	Debate: analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is not a cause of chronic daily headache. <i>Headache</i> , 2002 , 42, 547-54	4.2	33
20	A not so uncommon cause of thunderclap headache. <i>Headache</i> , 2002 , 42, 555	4.2	5
19	Ten most commonly asked questions about headaches associated with spontaneous cerebrospinal fluid leaks... with one bonus question!. <i>Neurologist</i> , 2002 , 8, 371-4	1.6	2
18	Treatment and management of cluster headache. <i>Current Pain and Headache Reports</i> , 2001 , 5, 83-91	4.2	49
17	Oral almotriptan in the treatment of migraine: safety and tolerability. <i>Headache</i> , 2001 , 41, 449-55	4.2	45
16	Carotid endarterectomy. Which patients can benefit?. <i>Postgraduate Medicine</i> , 2000 , 107, 97-100, 104-6, 109	3.7	1
15	Hypnic Headache: Another Indomethacin-Responsive Headache Syndrome?. <i>Headache</i> , 2000 , 40, 830-835	4.2	54
14	Hypnic headache: another indomethacin-responsive headache syndrome?. <i>Headache</i> , 2000 , 40, 830-5	4.2	58
13	Headache after resection of acoustic neuroma. <i>Headache</i> , 1999 , 39, 89-94	4.2	27
12	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. <i>Annals of Neurology</i> , 1999 , 46, 878-86	9.4	682
11	Three-dimensional measurement of essential tremor. <i>Movement Disorders</i> , 1999 , 14, 288-94	7	29

10	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease 1999 , 46, 878		2
9	Chronic paroxysmal hemicrania presenting as otalgia with a sensation of external acoustic meatus obstruction: two cases and a pathophysiologic hypothesis. <i>Headache</i> , 1998 , 38, 787-91	4.2	38
8	Extratrigeminal episodic paroxysmal hemicrania. Further clinical evidence of functionally relevant brain stem connections. <i>Headache</i> , 1998 , 38, 794-8	4.2	26
7	Headache as a symptom of ominous disease. What are the warning signals?. <i>Postgraduate Medicine</i> , 1997 , 101, 46-50, 55-6, 62-4	3.7	27
6	Approach to History Taking and the Physical Examination15-25		
5	Medication Overuse Headache in the Emergency Department99-109		
4	Primary stabbing headache116-119		
3	Botulinum toxin type A for the prophylactic treatment of primary headache disorders229-242		
2	A review of the clinical efficacy and tolerability of almotriptan in acute migraine		2
1	Migraine Comorbidities in Children122-131		1